GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Running, not enrolling · Phase 2/Phase 3

Conditions studied: Severe Obesity, Obesity, BMI Greater Than 30

In brief

The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who continue with the current standard of care for patients who have previously undergone Gastric Bypass Surgery.

Key facts

Study ID

NCT06162715

Run by

Vanderbilt University Medical Center

People needed

30

Starts

2024-10-30

Expected to finish

2027-12-01

Last updated by the study team

2026-08-04

Who can join

Age: 25 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be able to understand and provide informed consent.
• BMI > 30 12 months after bariatric surgery.
• Age > 25 and < 65
• Patients undergoing primary Roux-en-Y Gastric Bypass

You may not qualify if…

• Inability or unwillingness of a subject to give written informed consent or comply with the study protocol.
• Diagnosis of type I Diabetes
• Revisional bariatric surgery (prior adjustable gastric band, sleeve gastric, vertical banded gastroplasty).
• Use of medications for type 2 di
• Hemoglobin A1c > 8.5 in last 3 months.
• Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months As this would preclude patients from undergoing bariatric surgery.
• Personal history of pancreatitis as determined by history.
• Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2
• Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period.
• Use of systemic glucocorticoids in the past 28 days
• Myocardial infarction, unstable angina, stroke, or heart failure (NYHA class II) within 1 year by history.
• History of solid organ transplant.
• History of physician-diagnosed malignancy (other than excised non-melanoma skin cancer) in the past 5 years.
• Current uncontrolled hypertension (systolic >150, diastolic >90) or untreated hyperthyroidism.
• Current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.
• Screening creatinine elevation with EGFR < 60 at time of randomization.
• Tobacco use in last 12 months
• Pregnancy
• Prisoners
• Unable or unwilling to follow-up
• Unable to understand English/Spanish

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.